Literature DB >> 8562928

Analysis of the Bruton's tyrosine kinase gene promoter reveals critical PU.1 and SP1 sites.

A Himmelmann1, C Thevenin, K Harrison, J H Kehrl.   

Abstract

The gene defective in X-linked agammaglobulinemia (XLA) encodes a novel protein kinase termed Bruton's tyrosine kinase (Btk). Whereas the XLA phenotype is confined to abnormalities of B-cell development and function, Btk is expressed not only in B-lymphocyte lineage but also in myeloid lineage cells. The first 450 basepairs of the Btk promoter fused to a luciferase gene displayed a similar cell-type specificity. Critical binding sites for the transcription factors PU.1 and Sp1 were identified in the proximal portion of the Btk promoter upstream of a cluster of transcriptional start sites. Mutation of either the PU.1 or Sp1 site markedly reduced the activity of a Btk promoter-luciferase reporter construct in transfection experiments. In addition, PU.1 directly transactivated the Btk promoter, and deletion of the PU.1 binding site abolished this effect. This study implicates PU.1 and Sp1 as major regulators of Btk expression and provides a foundation for further study of the regulation of this gene in XLA patients that lack Btk mRNA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8562928

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Successful hematopoietic cell transplantation in a patient with X-linked agammaglobulinemia and acute myeloid leukemia.

Authors:  Rolla F Abu-Arja; Leah R Chernin; Ghada Abusin; Jeffery Auletta; Linda Cabral; Rachel Egler; Hans D Ochs; Troy R Torgerson; Jesus Lopez-Guisa; Robert W Hostoffer; Haig Tcheurekdjian; Kenneth R Cooke
Journal:  Pediatr Blood Cancer       Date:  2015-04-20       Impact factor: 3.167

Review 2.  X-linked agammaglobulinemia: lack of mature B lineage cells caused by mutations in the Btk kinase.

Authors:  C I Smith; C M Bäckesjö; A Berglöf; L J Brandén; T Islam; P T Mattsson; A J Mohamed; S Müller; B Nore; M Vihinen
Journal:  Springer Semin Immunopathol       Date:  1998

3.  Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders.

Authors:  Blythe D Sather; Byoung Y Ryu; Brigid V Stirling; Mikhail Garibov; Hannah M Kerns; Stéphanie Humblet-Baron; Alexander Astrakhan; David J Rawlings
Journal:  Mol Ther       Date:  2010-12-07       Impact factor: 11.454

4.  Nfkb1 activation by the E26 transformation-specific transcription factors PU.1 and Spi-B promotes Toll-like receptor-mediated splenic B cell proliferation.

Authors:  Stephen K H Li; Ali K Abbas; Lauren A Solomon; Gaëlle M N Groux; Rodney P DeKoter
Journal:  Mol Cell Biol       Date:  2015-03-02       Impact factor: 4.272

5.  B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia.

Authors:  Hannah M Kerns; Byoung Y Ryu; Brigid V Stirling; Blythe D Sather; Alexander Astrakhan; Stephanie Humblet-Baron; Denny Liggitt; David J Rawlings
Journal:  Blood       Date:  2010-01-21       Impact factor: 22.113

6.  MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.

Authors:  Mariateresa Fulciniti; Nicola Amodio; Rajya Lakshmi Bandi; Mansa Munshi; Guang Yang; Lian Xu; Zachary Hunter; Pierfrancesco Tassone; Kenneth C Anderson; Steven P Treon; Nikhil C Munshi
Journal:  Blood       Date:  2014-03-12       Impact factor: 22.113

Review 7.  Bruton's Tyrosine Kinase and Its Isoforms in Cancer.

Authors:  Xianhui Wang; Leila Kokabee; Mostafa Kokabee; Douglas S Conklin
Journal:  Front Cell Dev Biol       Date:  2021-07-08

8.  Differential gene expression analysis by RNA-seq reveals the importance of actin cytoskeletal proteins in erythroleukemia cells.

Authors:  Vanessa Fernández-Calleja; Pablo Hernández; Jorge B Schvartzman; Mario García de Lacoba; Dora B Krimer
Journal:  PeerJ       Date:  2017-06-27       Impact factor: 2.984

9.  Btk expression is controlled by Oct and BOB.1/OBF.1.

Authors:  Cornelia Brunner; Thomas Wirth
Journal:  Nucleic Acids Res       Date:  2006-03-31       Impact factor: 16.971

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.